Clinical trials: Rectum Neoplasm
Rectal Cancer
Simultaneous Integrated Boost Preoperative Radiotherapy for Rectum Cancer
The investigators propose a randomized non-inferiority trial that compares preoperative Fluoro Uracil (FU)-based chemoradiotherapy to radiotherapy with a simultaneous integrated boost.
- Trial name
- RectumSIB (NCT01224392)
- Testing
- Chemoradiotherapy, Radiotherapy with boost
- Where
- 2 sites in Belgium
- Volunteers
- 156 people
- Sponsor
- Universitair Ziekenhuis Brussel
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer
Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00060411
- Testing
- erlotinib hydrochloride, fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, MSS
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
This is a multi-center, non-randomised Phase 1b study to evaluate the safety and tolerability of ATP128 alone or in combination with BI 754091 and of heterologous prime-boost ATP128 + VSV-GP128 in combination with BI 754091.
- Conditions
- Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Trial name
- KISIMA-01 (NCT04046445)
- Testing
- ATP128, BI 754091, VSV-GP128
- Where
- 12 sites in United States, Belgium and 2 more
- Volunteers
- 96 people
- Sponsor
- Amal Therapeutics
Colorectal Cancer
ColoCare Study - Colorectal Cancer Cohort
ColoCare is an international prospective cohort study of stage I-IV colorectal cancer patients (ICD-10 C18-C20).
- Trial name
- NCT02328677
- Where
- 7 sites in United States, Germany
- Volunteers
- 5,000 people
- Sponsor
- University of Utah
Colo-rectal Cancer
Safety & Efficacy of a Novel Asymmetrical Linear Stapler (NALS) for Securing Distal Resection Margin in Laparoscopic Rectal Cancer Surgery: Pilot Study
Through the use of a novel asymmetrical linear stapler (NALS, Meditulip co. Ltd.), we aim to prove that true distal margins greater than 1cm may be harvested more readily and easily compared to the conventional staplers.
- Trial name
- NCT06709170
- Testing
- Novel asymmetrical linear stapler, Signia™
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Rectal Cancer, Neoadjuvant Therapy
Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer
Background There is currently no reliable means to restage rectal cancers after neoadjuvant chemoradiation. There are still no reliable methods to identify patients with pCR before radical surgery.
- Conditions
- Rectal Cancer, Neoadjuvant Therapy, Complete Remission, Metastasis
- Trial name
- BIOPSY (NCT04743102)
- Testing
- multi-points and full-thickness Biopsy, traditional cCR
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Beijing Chao Yang Hospital
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Prostate Cancer
Rectal Spacer Hydrogel Before Radiation Therapy in Reducing Radiation Dose to the Rectum in Patients With Prostate Cancer
This phase II trial studies the effect of rectal spacer hydrogel before radiation therapy in reducing radiation dose to the rectum in patients with prostate cancer.
- Trial name
- NCT05224869
- Testing
- Medical Device Usage and Evaluation, CT simulation, Stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Total Mesorectal Excision, Rectal Neoplasms
RATME Vs LATME in Middle and Low Rectal Cancer
This is a multicenter, superior, randomized controlled trial designed to compare Robotic-assisted total mesorectal excision (RATME) and laparoscopic-assisted total mesorectal excision (LATME) for middle and low rectal cancer.
- Conditions
- Total Mesorectal Excision, Rectal Neoplasms, Robotic Surgical Procedures, Laparoscopy
- Trial name
- NCT06105203
- Testing
- Robotic-assisted total mesorectal excision, laparoscopic-assisted total mesorectal excision
- Where
- China
- Volunteers
- 1,026 people
- Sponsor
- The First Hospital of Jilin University
Anal Cancer Squamous Cell
Proton Versus Photon Therapy in Anal Squamous Cell Carcinoma
Dosimetric studies suggest that radiotherapy with protons has a potential to reduce side effects compared to treatment with photons for patients with anal carcinoma (AC).
- Trial name
- SWANCA (NCT04462042)
- Testing
- Proton radiotherapy, Photon radiotherapy
- Where
- 4 sites in Sweden
- Volunteers
- 100 people
- Sponsor
- Umeå University
Gastric Cancer, Pancreatic Cancer
Chemoradiation-Induced Nausea and Emesis: Quality of Life
The primary objectives of this study are: 1. To assess the preferences of cancer patients scheduled to receive chemoradiation and caregiver controls for side-effects of chemoradiation. 1.
- Conditions
- Gastric Cancer, Pancreatic Cancer, Cervical Cancer, Vulvar Cancer
- Trial name
- NCT00394602
- Testing
- Interview, Questionnaire
- Where
- United States
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Radiation Therapy, Cancer
Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)
Collect blood samples and associated clinical data prior to, during, and post radiation treatment.
- Conditions
- Radiation Therapy, Cancer, Cancer of Anus, Cancer of Bladder
- Trial name
- RADIANT (NCT03133286)
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- DxTerity Diagnostics
Rectal Neoplasm
Prospective Multicenter Randomized Controlled Trial On Two-Stage Turnbull-Cutait Coloanal Anastomosis For Rectal
The aim of this study is to decrease the morbidity by 30% using the Turnbull-Cutait procedure in comparison to the standard surgery for low rectal cancer.
- Trial name
- TURNBULL-BCN (NCT01766661)
- Testing
- Hand-sewn coloanal anastomosis, Two staged Turnbull-Cutait procedure, Ultralow anterior rectal resection with total mesorectal excision
- Where
- 4 sites in Italy, Spain
- Volunteers
- 92 people
- Sponsor
- Hospital Universitari de Bellvitge
Rectal Adenocarcinoma
Avoiding Surgery in Rectal Cancer After Pre-Operative Therapy
The objective of Timing and Deferral of Rectal Surgery Following a Continued Response to Pre-operative CRT study is to establish the time to maximum tumour response following CRT, and to investigate whether surgery can be safely…
- Trial name
- NCT01047969
- Testing
- Adjuvant Chemotherapy, Surgery
- Where
- United Kingdom
- Volunteers
- 99 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Anal Carcinoma, Cervical Carcinoma
Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls
This research trial studies extended follow up of young women in Costa Rica who received vaccine for human papillomavirus types 16 and 18 and unvaccinated controls.
- Conditions
- Anal Carcinoma, Cervical Carcinoma, Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma
- Trial name
- NCT00867464
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Long-term Follow-up
- Where
- Costa Rica
- Volunteers
- 8,670 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer Stage I
Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer
This study is a single-center, single-arm, prospective clinical trial designed to evaluate the efficacy of local excision followed by postoperative chemoradiotherapy in patients with early-stage low/ultra-low rectal cancer.
- Trial name
- NCT06949098
- Testing
- Local Tumor Resection, Radiotherapy, Chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hebei Medical University Fourth Hospital
Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma
Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial
This trial screens patients with colon or rectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable) for genetic mutations for recommendation to a molecularly assigned…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Trial name
- NCT03765736
- Testing
- Genetic Testing
- Where
- 18 sites in United States
- Volunteers
- 199 people
- Sponsor
- Academic and Community Cancer Research United
Colorectal Cancer
Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00544700
- Testing
- bevacizumab, no maintenance
- Where
- 29 sites in Switzerland
- Volunteers
- 265 people
- Sponsor
- Swiss Cancer Institute
Rectal Cancer
Laparoscopic Assisted Transanal Resection of Rectal Cancer With Total Mesorectal Excision
Rectal cancer is one of the frequent malignant neoplasms ,Total mesorectal excision (TME) has become the gold standard treatment for middle and lower rectal cancers.
- Trial name
- NCT03171298
- Testing
- Laparoscopic Assisted Transanal Total Mesorectal Excision
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Colorectal Cancer, Pancreatic Cancer
Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. QS21 may improve the ability of the immune system to respond to disease. Combining vaccine therapy with QS21 may kill more tumor cells.
- Trial name
- NCT00006387
- Testing
- QS21, ras peptide cancer vaccine
- Volunteers
- 7 people
- Sponsor
- Fox Chase Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.